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Summary In a study involving 50 breast cancer tumours, we compared two oestrogen receptor (ER) detection methods developed by us - a
microplate immunoenzymometric assay (EIA96) and an immunohistochemistry kit (HistoCIS-ER) - with the radioligand assay (RLA), the
Abbott immunoenzymometric assay ER-EIA and the reverse transcriptase polymerase chain reaction technique (RT-PCR). Among the three
ER protein cytosolic assays (EIA96, ER-EIA and RLA), the two ElAs showed the best agreement (y = 1.086x - 7.840; r2 = 0.876). At the
calculated optimal cut-off values (8 and 14 fmol mg-1 protein for EIA96 and RLA respectively), EIA96 was more sensitive than RLA (0.94 for
EIA96, 0.88 for RLA), but slightly less specific (0.82 for EIA96, 0.94 for RLA). The Cox logistical regression model applied to EIA96, RLA and
RT-PCR showed that EIA96 discriminated the best between ER-EIA+ and ER-EIA- samples. The RT-PCR technique and HistoCIS-ER both
had a positivity-negativity concordance of 86% with EIA96.
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The determination of the oestrogen receptor (ER) content of a
breast tumour is ofclinical interest in two respects. First, the pres-
ence of ER is an independent prognostic factor (Knight et al,
1977); the prognosis ofpatients with ER-positive tumours is more
favourable than that of patients with ER-negative tumours
(Horwitz et al, 1975). On the other hand, the ER/progesterone
receptor (PgR) status is a predictor of response to hormone
therapy: 70-80% of patients with ER+/PgR+ breast tumour biop-
sies respond to hormonal treatmentcompared with 10% ofpatients
with ER-/PgR- tumours (McGuire et al, 1991).
The oestrogen receptor is a 66-kDa ligand-regulated transcrip-
tional factor that is encoded by a gene composed of eight exons
(Green et al, 1986). Among the six domains of ER (A-F), the C
region is responsible for DNA binding and the E domain holds the
ligand-binding function. Many mutations and variants of the ER
mRNA have been described in mammary tumours and in breast
cancer cell lines (Sluyser, 1995), as well as in normal breast tissue
(Pfeffer et al, 1995). The vast majority of these mutations arises
from an alternative splicing of the transcript, leading to the dele-
tion of one or more exons. This phenomenon is of variable extent
and has been described for exons 2, 3, 4, 5 and 7. The proteins
encoded by aberrantly spliced mRNAs are truncated or internally
deleted. The expression of variant receptors in heterologous
systems reveals dominant-positive ERs that are transcriptionally
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encoded by an exon 5 deleted mRNA; Fuqua et al, 1991), whereas
ERAE7 is dominant negative as it is transcriptionally inactive and
prevents the action of the wild-type receptor (Wang et al, 1991;
Fuqua et al, 1992). Apart from these splicing variants, ponctual
mutations and nucleotide insertions have also been described
(Sluyser, 1995). Some variant receptors have also been found in
normal tissues (Hoshino et al, 1995; Pfeffer et al, 1995) raising the
question whether the relative levels of variant ERs in tissues may
be important in relation to loss ofhormone dependence.
The ER assay can be carried out at the protein level as well as at
the mRNA level. In the case of protein detection, two kinds of
techniques are widely used: quantitation ofER in cytosol extracts
oftumour tissue and immunohistochemistry on tissue sections.
The receptor assay in cytosol extracts can be made using two
techniques based on different principles. The reference method is
the radioligand assay (RLA), which detects the ligand-binding
function by measuring the number of specific binding sites and
their affinity for the ligand. An enzyme immunoassay (EIA)
detects the physical presence ofERs when the epitopes recognized
by the antibodies remain intact; these receptors can therefore be
functionally inactive. The ER-EIA kit developed by the Abbott
Laboratories recognizes epitopes localized in domains D and E of
ER (regions 250-302 and 463-526; Leclercq et al, 1986).
Anti-ER monoclonal antibodies are also used in immunohisto-
chemistry to visualize the tissue distribution and subcellular local-
ization ofthe receptor on tissue sections. The percentage ofstained
cells and the staining intensity allow a semiquantification. The
information provided by immunohistochemistry is complementary
to the results obtained with quantitative methods carried out on
cytosol extracts.
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We have developed an immunoenzymometric assay for ER,
EIA96 (Delage et al, 1996), and an immunohistochemistry kit,
HistoCIS-ER both ofwhich recognize the B region ofthe receptor.
The aim ofthe present study was to compare EIA96 with the other
quantitative detection techniques of the ER protein (RLA, ER-
EIA) and with the RT-PCR applied to the mRNA region that codes




Receptors were measured in breast adenocarcinoma tissue biop-
sies. The samples were obtained by surgical removal and immedi-
ately frozen in liquid nitrogen before transferral to the laboratory.
None of the patients in this study had received chemo- or radio-
therapy before surgical treatment. Each piece was histologically
examined by the pathologist in order to check the presence and
appearance oftumoral tissue.
Reagents
We used the following buffers: phosphate-buffered saline (PBS):
disodium hydrogen phosphate/potassium dihydrogen phosphate
50 mmol 1-1, sodium chloride 150 mmol 1-', pH 7.4; TEM buffer:
Tris-HCl 10 mmol 1-1, EDTA 1.5 mmol 1-1, sodium molybdate
5 mmol 1-', monothioglycerol 0.1 ml 1-1, pH 7.4 (TEGM buffer was
made as TEM buffer by replacing monothioglycerol by 100 ml 1-1
glycerol); citrate buffer: citric acid monohydrate 100 mmol 1-', tri-
sodium citrate dihydrate 100 mmol 1-', pH 6.0; buffer A: disodium
hydrogen phosphate/sodium dihydrogen phosphate 50 mmol 1-1,
potassium chloride 400 mmol 1-1, pH 7.0; buffer B: disodium
hydrogen phosphate/sodium dihydrogen phosphate 50 mmol 1-1,
pH 8.0; xylene cyanol blue: xylene cyanol blue 0.25%,
bromophenol blue 0.25%, EDTA 1 mmol 1-1, glycerol 50%,
pH 8.0; buffer 67: Tris-HCl 670 mmol 1-l, ammonium sulphate
166 mmol 1-1, magnesium chloride 67 mmol 1-1, pH 8.8; buffer 27:
Tris-HCl 670 mmol 1-', ammonium sulphate 166 mmol 1-', magne-
sium chloride 27 mmol 1-1, pH 8.8. Buffers 10 x TAE and 10 x
TBE were purchased from Interchim (Asnieres, France).
17P-[2,4,6,7-3H]oestradiol, sp. act. 3.3 x 10'5-3.9 x 10's Bq
mol- , was purchased from Amersham (Les Ulis, France). Inert
steroids and diethylstilboestrol were obtained from Roussel-Uclaf
(Romainville, France). The radiolabelled steroid was purified by
paper chromatography, eluted with absolute ethanol and stored
under nitrogen in amber vials at -20°C until use. Inert steroids
were prepared as 1 mmol 1-1 solutions and stored at 40C.
Reverse transcriptase polymerase chain reaction
(RT-PCR)
RNA extraction
Frozen tumour specimens were homogenized using aPolytron 2000
(BioblockScientific, Illkirch Graffenstaden, France) in Trizol (0.1 g
per 1 ml; LifeTechnologies, Eragny, France). After a 5-min incuba-
tion at room temperature, 0.2 volume ofchloroform was added and
the tubes were shaken. After a 2- to 3-min incubation at room
temperature, a 20-min centrifugation at 12 000 g at 40C was
performed using aTL-100.4 rotorin aTL-100centrifuge (Beckman
Instruments, Gagny, France). The aqueous superior phase was
transferred to a new tube and one volume ofisopropanol was added.
After a 16- to 18-h incubation at-20°C, a 20-min centrifugation at
20 000g at 4°C was performed. The supematant was discarded and
the pellet washed with 1 ml of a 75% ethanol solution. After a 15-
min centrifugation at 12 000 g at 4°C, the pellet was dried and
dissolved in 50-100 1l of sterile diethylpyrocarbonate (DEPC)-
treated water. Samples were heated to 60°C for 10 min.
The RNA concentration was determined spectrometrically
(Spectronic Genesys 5, Bioblock Scientific) using the absorbance at
260 nm of5 gl ofRNA diluted in 500gl ofDEPC water. The RNA
concentration was adjusted to 1 ,ug pl-l in DEPC water. The absence
of protein contamination was checked using the ratio A2WJA2809
which had to be higher than 1.6. Samples were stored at -80'C.
An aliquot (1 gl) of RNA was added to 10 gl of water and 1 p1
of xylene cyanol blue. Samples were applied on a 2% agarose gel
and electrophoresed for 15 min in 1 x TAE buffer at 100 V (Super-
Sub HE100, Hoefer, Pharmacia Biotech, Uppsala, Sweden). The
gel was stained with ethidium bromide. A good RNA extraction
produced three bands (28S, 18S, 4S) of decreasing intensity.
Deteriorated samples were eliminated.
Reverse transcription
An aliquot (1 ,l) of RNA (1 gg pl-') or 1 p1 of sterile water
(control) was mixed with 2 g1 of a 10 mmol 1-1 dNTP mix (Life
Technologies), 1 pl of 100 ,umol 1-1 PdN6 random hexamer
(Boehringer Mannheim France SA, Meylan, France), 2 p1 of
buffer 67 and 12 g1 of sterile water. After an initial incubation at
70°C for 5 min and a briefcentrifugation, samples were put on ice.
An aliquot (1 p1) of human placental ribonuclease inhibitor
(120 U p1', Amersham) and 1 p1 of murine moloney leukaemia
virus (MuML V) reverse transcriptase (200 U p1-', Life
Technologies) was added. Reverse transcription was allowed to
proceed for 30 min at 42°C and another 5 min at 75°C. Samples
were put on ice after a brief centrifugation. A total of 480 pl of
DEPC water was added and cDNA samples were stored at -80°C.
Polymerase chain reaction
An aliquot (10 p1) ofcDNA was added to 2 pl of 10 mmol 1-1 dNTP
mix, 1 pl of each of the 50 pmol p1' ER primers (no. 1 and no. 2,
Genosys Biotechnologies, The Woodlands, TX, USA), 2 pl of each
of the 50 pmol p1-1j2-microglobulin primers (no. 3 and no. 4,
Genosys Biotechnologies), 10 pl of buffer 27, 0.5 pl of Taq DNA
polymerase (2.5 U p1-, Life Technologies), 71.5 p1 of sterile
distilled water and 100 pl of vaselin oil (Prolabo, Paris, France).
The sense ER primer no. 1 (5'-ACTCGCTACTGTGCAGTGTG-
CAATG-3') corresponds to ER cDNA 544-568 (Greene etal, 1986).
ER primer no. 2 (5'-CCTCTFCGGTCTT'ITCGTATCCCAC-3')
represents the antisense strand of the ER cDNA sequence 758-782
(Greene et al, 1986). The sense V2-microglobulin primer no. 3 (5'-
CATCCAGCGTACTCCAAAGA-3') corresponds to fr-microglob-
ulin cDNA 97-116 (Gussow et al, 1987). P2-Microglobulin primer
no. 4 (5'-GACAAGTCTGAATGCTCCAC-3') represents the anti-
sense strand of the 32-microglobulin cDNA sequence 242-261
(Gussow et al, 1987). After an initial denaturation at 94°C for 30 s,
each cycle ofamplification consisted in a 50-s denaturation at 940C,
followed by 50 s of annealing (58°C) and 20 s of extension (72°C)
steps. After 35 cycles, the final product was extended for 10 min
(70°C; Temp-tronic Thermolyne, Bioblock Scientific). The
following controls were included: (1) T47D cell line (ER+, 02-
microglobulin+); (2) HT1080cell line (ER-, ,B2-microglobulin+); (3)
sterile water (PCR-); (4) RT-control product.
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Table 1 Variable distribution (ER protein assays)
Minimum Q25 Median 075 Maximum
RLA 0 3.6 23.5 57.9 645
EIA96 0 4.1 25.0 54.6 478
ER-EIA 1 10.2 28.5 74.5 330
Table 2 Statistics and tests at the optimal cut-off value of each method
Statistics at the optimal RT-PCR RLA EIA96
cut-off value
Optimal cut-off value 0.21 14 8
Optimalx2 20.06 31.43 30.01
Corrected P-value 9.9 x 10-4 6.6 x 10s5 7.3 x 10-5
K 0.62 0.79 0.77
Standard error 0.12 0.09 0.10
P-value 2.4 x 10-7 < 108 < 10-8
P+ 0.89 0.92 0.93
P- 0.73 0.86 0.85
Area under ROC 0.793 0.910 0.881
Standard error 0.063 0.041 0.052
Sensitivity 0.94 0.88 0.94
Specificity 0.65 0.94 0.82
LR 2.66 14.94 5.32
VPP 0.84 0.97 0.91
1np 0.85 0.80 0.88
%CC 84 90 90
LR, likelihood ratio; VPP, positive predictive value; VP, negative predictive
value; % CC, percentage of correctly classified tumours.
An aliquot (100 ,l) of the PCR product was added to 10 gl of
xylene cyanol blue. Of this mixture, 20 g1 was applied on a 2%
agarose gel and electrophoresed in 1 x TAEbufferfor 1 h at 100 V.
The gel was stained with ethidium bromide. UV visualization
allowed checking of the PCR efficiency (integrity of I2-
microglobulin and ofeach control).
An aliquot (20 pl) of the PCR product-xylene cyanol blue
mixture was then applied on a 7% polyacrylamide gel prepared as
follows: 10.5 ml of 40% acrylamide (38/2, Appligene, Illkirch
Graffenstaden, France), 6 ml of 10 x TBE, 43.5 ml of sterile
distilled water, 360 gl of ammonium peroxidisulfate (E Merck,
Darmstadt, Germany), 45 gl ofTemed (Sigma Chemical, St Louis,
MO, USA). Samples were electrophoresed for 16 to 18 h at 4°C
(20 V). After ethidium bromide coloration, the density ofeach ER
and 32-microglobulin band was estimated using the BIO-PROFIL
system (BIOID logiciel, Vilber Lourmat, Torcy, France). For each
sample, the R ratio was calculated: R = density of ER
band-density ofP2-microglobulin band.
Radioligand method and oestrogen receptor
immunoenzymometric assays
Cytosolpreparation
An aliquot (0.2-0.3 g) of each frozen tumour specimen was
homogenized for 15 s using a Polytron 2000 (Bioblock Scientific)
in cold TEGM buffer (10 ml g- tumour). Thecytosol was obtained
by ultracentrifuging the homogenate at 105 000 g for 1 h at
40C (TL-100.4 rotor in a TL-100 ultracentrifuge, Beckman
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Figure I Correlation between EIA96 and ER-EIA, EIA96 and RLA, and RLA
and ER-EIA on 50 cytosols of mammary tumours. A one-degree polynomial
curve fit was used. n = 50; Q--O-, RLA = 1.173 x ER-EIA - 13.398,
r2 = 0.759; -_-, EIA96 = 1.086 x ER-EIA - 7.840, r2 = 0.876; --*--,
EIA96 = 0.777 x RLA + 13.170, r2 = 0.814
Radioligand method
Cytosol aliquots were distributed in 96-well microtitre plates. The
presence and the number of ER binding sites were determined by
the RLA, as described previously (Delage et al, 1996), and
according to the recommendations of the European Organization
for the Research and Treatment ofCancer (EORTC Breast Cancer
Cooperative Group, 1980). The results were expressed as fmol
bound oestradiol mg-' ofcytosolic protein.
Microtitre plate EIA96 assayprotocol
All steps were carried out at 4°C in 96-well microtitre plates
(Greiner-Labortechnik, Frickenhausen, Germany), as described
previously (Delage et al, 1996). The mouse monoclonal antibodies
involved in EIA96 were B10 (Ali et al, 1993), directed against
amino acids 151-165 of the B domain of the human ER (Krust et
al, 1986), and AER314 (Bioprobe, Amstelveen, The Netherlands;
Abbondanza et al, 1993), directed against an epitope distinct from
BlO in the B domain (region 121-168). Calibrated solutions of
recombinant human ER expressed in yeast strain TGY14 were
used as standards (Metzger et al, 1988). The results were
expressed as fmol ER mg-' ofcytosolic protein.
Abbott ER-EIA
ER was assayed with the Abbott ER-EIA monoclonal kit
(Laboratories Abbott, Rungis, France), according to the manufac-
turer's instructions. ER concentration was expressed as fmol mg-'
ofcytosolic protein.
Protein concentration
The protein concentration of cytosols was determined using the
BCA protein assay kit (Pierce Europe, Oud Beijerland, The
Netherlands), according to the manufacturer's instructions. Bovine
serum albumin supplied in the kit was used as the calibrator.
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Immunohistochemistry
For each tumour, one or two representative paraffin blocks were
chosen, with adjacent non-tumoral tissue (internal control). Four-
micrometre tissue sections were mounted onto APES-pretreated
slides (3-aminopropylethoxysilane, Sigma Chimie, Saint Quentin
Fallavier, France) and dried at 55°C overnight. The slides were
deparaffinized for 20 min in toluene, 2 x 5 min in 100% ethanol,
and washed for 5 min in tap water. They were then put in citrate
buffer and heated in a microwave oven for 4 x 5 min. After each
5-min cycle, the level was topped up with distilled water. Slides
were left to cool at room temperature for 20 min, incubated for
another 20 min in hydrogen peroxide 2% in methanol, and washed
for 3 min in tap water. The sections were then incubated at room
temperature for 10 min with a blocking reagent [bovine serum
albumin (BSA) 1% in PBS]. Excess reagent was discarded and
the slides were incubated with primary antibody (B10) diluted in
PBS/BSA (2 ,ug ml-') at room temperature for 1 h in a humidified
chamber. They were then washed for 2 x 5 min in PBS, incubated
at room temperature with a biotinylated goat anti-mouse antibody
(StreptABComplex Duet, Dako, Trappes, France), rinsed for
2 x 3 min in PBS and then incubated for another 30 min at room
temperature in the chamber with the streptavidin-biotin-peroxidase
complex from the same kit. The slides were rinsed for 2 x 3 min in
PBS, and finally incubated for 10 min with a DAB solution
(diaminobenzidine, Biosys, Compiegne, France). After one wash
with tap water, the slides were counterstained with Hemalun
(E Merck) for 10 s, and rinsed in tap water. The slides were
mounted in Aquatex (E Merck). A semiquantitative evaluation was
carried out by thepathologist to estimate the percentage ofpositive
cells and the staining intensity. A section was considered ER+ if
more than 10% ofcells were stained.
Data analysis
Taking ER-EIA as the reference technique (cut-off value =
15 fmol mg-1 protein), the optimal cut-off value ofthe three other
quantitative techniques (X = EIA96, RLA or RT-PCR) was deter-
mined by considering each ofthe distinct values obtained for X as
the cut-off value and by calculating the associated X2 with one
degree of freedom. The value associated with the maximum x2
was taken as the cut-off value. The associated P-value was
corrected following the Hilsenbeck and Clark (1996) method, by
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Figure 2 Relationship between RT-PCR and EIA96 on 50 mammary
tumours. The calculated optimal cut-off values are indicated for each method
then considered as true positive (TP), ER-EIA /X as true negative
(TN), ER-EIA-/X+ as false positive (FP) and ER-EIA+/X- as false
negative (FN). The sensitivity and the specificity were the true
positive rate [TPR = TP/(TP + FN)] and the true negative rate
[TNR = TN/(TN + FP)] respectively. The positive predictive value
of an X technique [Vpp = TP/(TP + FP)] was the probability that a
tumour sample assayed ER+ by the X technique was really ER+.
On the other hand, the negative predictive value [V = TN/
(TN + FN)] was the probability that a tumour sample assayed
ER- by the X technique was really ER-. The likelihood ratio (LR)
was equal to sensitivity/(l - specificity). The receiver-operating
characteristic (ROC) curve, which was plotted as sensitivity
against (1 - specificity), gave the discriminatory capacity ofa test.
The area under the ROC curve showed the probability that a
random ER+ tumour had been correctly classified.
The agreement between each ofthe three methods and ER-EIA
was evaluated using the agreement coefficient K, with its standard
error and the average ofpositive and negative agreements (P+ and
P- respectively).
A one-degree polynomial curve fit was used to correlate the
data obtained with the methods quantifying the ER protein
(EIA96, ER-EIA, RLA).
The Cox (1970) logistical regression model was applied to
determine which technique among RLA, EIA96 and RT-PCR
best discriminated ER-EIA+ from ER-EIA- samples. The
Table 3 Samples with at least one discrepant value in one of the five methods
Tumour EIA96 (fmol mg-') ER-EIA (fmol mg-1) RLA (fmol mg-') RT-PCR HistoCIS-ER
7 34.9 38.0 0.0 0.61 80%
12 24.6 15.0 14.0 0.20 0%
13 2.3 2.0 3.2 0.38 0%
16 16.1 18.0 5.3 0.32 80%
18 0.6 2.0 0.0 0.84 100%
27 22.6 13.0 0.0 0.04 0%
37 4.0 26.0 30.0 0.16 50%
46 5.4 10.0 112.4 0.55 80%
50 21.1 23.0 14.0 0.07 90%
51 4.0 2.0 3.6 0.38 20%
53 0.0 43.0 17.4 0.33 40%
Discrepant values are indicated in bold.
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Lemshow-Hosmer test (Lemshow and Hosmer, 1982), the Harrel
c index (Harrel et al, 1982) and the Goodman-Kruskal correlation
index allowed checking to see ifthe model used was appropriate.
RESULTS
The oestrogen receptor was detected in 50 mammary tumours
using five different methods: determination of the ER protein
concentration in cytosolic extracts using the radioligand binding
assay (RLA) and two immunoenzymometric techniques (EIA96,
ER-EIA), quantification by RT-PCR of the ER mRNA region
coding for domain C, immunohistochemical detection of the
receptor on sections with the B1O antibody (HistoCIS-ER).
Assay of ER protein (RLA, EIA96, ER-EIA)
Variable distribution
Table 1 lists the minimum, maximum, lower (Q25) and upper
(Q75) quartiles, and median values.
Determination ofoptimal cut-off values
Considering the maximum X2 values, the cut-off values of EIA96
and RLA were 8 fmol mg-' and 14 fmol mg-' respectively (Table
2). At the optimal cut-off value, EIA96 and RLA displayed a
substantial agreement with ER-EIA (K = 0.77 and 0.79 respec-
tively) and discriminated well between ER+ and ER- tumours (area
under ROC = 0.881 and 0.910 respectively). Furthermore, EIA96
was more sensitive than RLA at the optimal cut-offvalue (0.94 for
EIA96, 0.88 for RLA), but slightly less specific (0.82 for EIA96,
0.94 for RLA).
Correlations
The two immunoenzymometric techniques, EIA96 and ER-EIA,
showed the best correlation (Figure 1). Seven samples had at least
one discrepant value in one ofthe three methods (Table 3, samples
7, 12, 16, 27, 37, 46, 53).
Quantification of ER mRNA (RT-PCR)
For each tumour, the density of the ER band was divided by the
density ofthe P2-microglobulin band.
Determination ofthe optimal cut-offvalue
An optimal cut-offvalue of0.21 was established (Table 2). At this
value, the agreement between RT-PCR and ER-EIA was moderate
(K = 0.62); furthermore, the RT-PCR discriminatory ability was
lower than those of EIA96 and RLA (area under ROC = 0.793).
Although the RT-PCR sensitivity was identical to that ofEIA96 at
the cut-offvalue, its specificity was significantly lower.
Comparison with EIA96
Figure 2 shows the relation between the RT-PCR status and the
concentration found by EIA96. Seven samples had discrepant
results (14%): two tumours were RT-PCR-/EIA96+ (Table 3,
tumours 27, 50) and five were RT-PCR+/EIA96- (Table 3, tumours
13, 18,46,51, 53).
Coxlogistical regression model
The Cox logistical regression model applied to the 50 tumours
showed that, among the three techniques (EIA96, RLA, RT-PCR),
EIA96 best discriminated between ER-EIA+ and ER-EIA- samples
(insertion X2 associated P-value fixed at 5%).
The model also allowed the calculation of the P, probabilities
for each tumour according to the following relationship
P = prob(ER - EIA +/EIA96) = exp(bo + bx EIA96)
1 + exp (bo + b x EIA96)
withbo 1.832 (confidence interval = [-3.170; -0.495]) and b, =
0.133 [confidence interval = (0.052; 0.214), Table 4] and were
then classified in 0.10-long intervals. There was a good agreement
between the number ofpredicted ER-EIA+ values and the number
of observed ER-EIA + values in each interval (y (number of
predicted ER-EIA+ values) = 0.992x (number of observed ER-
EIA+ values) + 0.026, r2 = 0.992). A Lemshow-Hosmer statistic of
5.991 was found (P = 0.648 with eight degrees of freedom), indi-
cating a good fitting ofthe model with the data.
The probability for a random sample that the observed and
predicted values are in agreement was estimated by a Harrel c
index of 0.922 (standard error = 0.039). A Goodman-Kruskal
correlation index of0.843 was calculated from c.
500 T U
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Table 4 Cox logistical regression model
Pi Observed Observed Predicted Predicted
ER-ElA ER-EIA- ER-EIA+ ER -EIA-
[0.0;0.1] 0 0 0.00 0.00
[0.1;0.2] 1 8 1.45 7.55
[0.2;0.3] 1 5 1.31 4.69
[0.3;0.4] 1 1 0.69 1.31
[0.4;0.5] 1 0 0.47 0.53
[0.5;0.6] 1 0 0.57 0.43
[0.6;0.7] 2 0 1.27 0.73
[0.7;0.8] 2 1 2.25 0.75
[0.8;0.9] 3 2 4.21 0.79
[0.9;1.0] 21 0 20.76 0.24
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Figure 3 Relationship between the percentage of stained cells (HistoCIS-
ER) and EIA96 on 50 mammary tumours. The calculated optimal cut-off
value of EIA96 is indicated
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Immunohistochemistry (HistoCIS-ER)
The BlO antibody used for immunohistochemical detection is the
same as the EIA96 solid-phase antibody. The staining of the cells
was intranuclear. Except in some altered areas, non-specific
staining was not observed. Figure 3 shows the relation between the
HistoCIS-ER status and the concentration found by EIA96. Seven
samples had discrepant results (14%): two tumours were
HistoCIS-ER-/EIA96+ (Table 3, tumours 12, 27) and five were
HistoCIS-ER+/EIA96- (Table 3, tumours 18, 37, 46, 51, 53).
DISCUSSION
We developed a microtitre plate immunoenzymometric assay of
the oestrogen receptor, EIA96, using two antibodies directed
against the B domain of ER (Delage et al, 1996). This study is a
comparison of EIA96 with four other detection techniques for the
receptor, involving 50 mammary tumours. The five methods
compared can be classified in two groups: strictly quantitative
assays of ER, carried out on the cytosolic fraction (EIA96, ER-
EIA, RLA), and detection techniques for either the ER protein on
tissue sections (HistoCIS-ER) or for a region of the receptor
mRNA (RT-PCR).
The comparison ofEIA96 with the two other assays carried out
on the cytosolic fraction (RLA, ER-EIA) shows that the best-
correlated techniques are the immunoenzymometric methods,
EIA96 and ER-EIA. Assuming that ER-EIA is the reference
method, EIA96 discriminates ER+ from ER- samples better than
RLA does. EIA96 and ER-EIA rely on the same principle, i.e. the
detection of the receptor presence by immunological recognition,
very different from the RLA principle, which measures the
integrity of the hormone-binding function. In spite of these
methodological differences, EIA96 and RLA behave similarly at
the calculated optimal cut-off values: the agreement between the
two assays and ER-EIA is substantial; EIA96 is slightly less
specific but more sensitive than the RLA technique at the optimal
cut-off value. The observed agreement between EIA96 and the
most widely used assays (RLA and ER-EIA) argues in favour of
the reliability of EIA96 results, which is very important from a
clinical point ofview.
The comparison between EIA96 and HistoCIS-ER or RT-PCR
shows a positivity-negativity agreement of 86% in both cases.
Although HistoCIS-ER.is carried out on tissue sections instead of
cytosols, as is the case forEIA96, this technique also detects the B
domain of ER through B10, the EIA96 solid-phase antibody.
Concerning RT-PCR, many events can generate discrepant results
with EIA96. This technique measures a very different entity, i.e.
the mRNA region that codes for the C domain of the receptor.
Some discrepant results arise from the messenger lability when the
protein is still present or, in contrast, from a dysfunction of the
protein synthesis, the mRNA subsisting without being translated.
Nevertheless, the RT-PCR technique optimization allowed a
significant agreement with EIA96 to be reached.
Eleven tumours show at least one discrepant value in one ofthe
five compared techniques. Samples 18 and, to a lesser extent, 51
have negative results with the three cytosolic quantitative assays
of ER (EIA96, ER-EIA, RLA). On the other hand, the receptor
detection on sections by HistoCIS-ER and the amplification by
RT-PCR ofan mRNA region are positive. The hypothesis offalse-
positive results does not seem to be valid because ofthe specificity
of these two techniques. Indeed, a non-specific hybridization of
the primers seems very unlikely, considering their length; in addi-
tion the B10 antibody was described as exclusively ER specific by
Ali et al (1993). Finally, the histological characteristics of these
tumours cannot explain the discrepancies. The most likely hypoth-
esis would be a sampling heterogeneity because of the fact that a
large quantity ofeach tumour was necessary for the comparison of
the five techniques.
The discrepancies oftumours 12, 13, 16, 27, 37 and 50 are weak,
the values being quite close to the calculated optimal cut-offvalues.
These cut-off values were determined with regard to ER-EIA as a
reference technique with a limited number oftumours (50). A clin-
ical study involving a larger riumber of samples would allow the
calculation ofcut-offvalues with a better clinical significance than
the technical cut-offvalues determined in the present work.
Tumours 7, 46 and 53 show a wide discrepancy in one of the
values obtained with the assays carried out on the cytosolic frac-
tion. These discrepancies cannot arise from a sampling hetero-
geneity, because the three techniques were carried out on the same
cytosol, which was aliquoted immediately after preparation. The
histological data ofthese tumours show no atypical characteristics.
In addition, a new definition ofthe cut-offvalues would not allow
correction of the discrepancies. Thus, the origin of these
discrepant values remains unexplained.
The clinical importance of such discrepancies will have to be
evaluated on a larger series of tumours. Nevertheless, this study
confirms the results obtained in a previous work that compared
EIA96 with the other cytosolic assays of ER (RLA and ER-EIA;
Delage et al, 1996), and completes them by underlining the agree-
ment between EIA96 and other detection methods (HistoCIS-ER
and RT-PCR).
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